Is increasing the dose of entecavir effective in partial virological responders?

dc.contributor.authorErtürk, Ayşe
dc.contributor.authorAkdoğan, Remzi Adnan
dc.contributor.authorParlak, Emine
dc.contributor.authorCüre, Erkan
dc.contributor.authorCüre, Medine Cumhur
dc.contributor.authorÖztürk, Çınar
dc.date.accessioned2020-12-19T20:13:17Z
dc.date.available2020-12-19T20:13:17Z
dc.date.issued2014
dc.departmentRTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.descriptionPubMed: 24936126
dc.description.abstractObjective: To analyze the effect of increasing Entecavir (ETV) dosage in patients with chronic hepatitis B (CHB) who partially responded to ETV after 1 year. Methods: Twenty-three hepatitis B e antigen (HBeAg)-positive and 36 HBeAg-negative patients with CHB were treated with ETV 0.5 mg daily. After 1 year of the treatment, those with detectable hepatitis B virus (HBV-DNA) were randomized to either ETV 0.5 mg or 1 mg daily. The resistance to ETV was excluded. Both groups received ETV for 3 years. The groups were compared in aspects of undetectable DNA. Results: Group 1 was given 0.5 mg ETV and included 32 patients (20 HBeAg-negative and 12 HBeAg-positive). Group 2 was given 1 mg ETV and consisted of 27 patients (16 HBeAg-negative and eleven HBeAg-positive). Group 2 had more effective suppression of HBV-DNA while both groups had comparable rates of HBeAg loss (58% and 63% for group 1 and group 2, respectively) and alanine transaminase (ALT) normalization at the end of 4 years. Conclusion: Increasing ETV dose from 0.5 mg to 1 mg after 1 year of ETV treatment may provide an effective suppression of viral replication. © 2014 Erturk et al.
dc.identifier.citationErturk, A., Akdogan, R. A., Parlak, E., Cure, E., Cumhur Cure, M., & Ozturk, C. (2014). Is increasing the dose of Entecavir effective in partial virological responders?. Drug design, development and therapy, 8, 621–625. https://doi.org/10.2147/DDDT.S61045
dc.identifier.doi10.2147/DDDT.S61045
dc.identifier.endpage625
dc.identifier.issn1177-8881
dc.identifier.pmid24936126
dc.identifier.scopus2-s2.0-84901772505
dc.identifier.scopusqualityQ1
dc.identifier.startpage621
dc.identifier.urihttps://doi.org/10.2147/DDDT.S61045
dc.identifier.urihttps://hdl.handle.net/11436/4002
dc.identifier.volume8
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorErtürk, Ayşe
dc.institutionauthorAkdoğan, Remzi Adnan
dc.institutionauthorCüre, Erkan
dc.institutionauthorCüre, Medine Cumhur
dc.institutionauthorÖztürk, Çınar
dc.language.isoen
dc.publisherDove Medical Press Ltd.
dc.relation.ispartofDrug Design, Development and Therapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectChronic hepatitis b
dc.subjectEntecavir
dc.subjectPatient monitoring
dc.subjectTreatment
dc.titleIs increasing the dose of entecavir effective in partial virological responders?
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
ertürk-2014.pdf
Boyut:
498.31 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text